GLP-1-based therapies offer a pharmacological intervention that targets these mechanisms directly, allowing for more effective management of obesity
It should not be viewed as a universal energy booster, and it is not a substitute for diagnosis and treatment when fatigue, muscle weakness, or poor exercise tolerance have a medical cause
Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T, et al
SLC25A39 (14963-1-AP), ALAS1 (16200-1-AP), GCLC (12601-1-AP), HMOX1 (10701-1-AP), MRM1 (16392-1-AP), MRPL15 (18339-1-AP), MRPS7 (26828-1-AP), FDX1 (12592-1-AP), FECH (14466-1-AP) and LIAS (11577-1-AP) antibodies from Proteintech
Among tirzepatide users, the most commonly reported symptoms were similar: nausea (28.6%), fatigue (14.7%), vomiting (11.1%), constipation (12.9%), and diarrhea (12.5%)
Accessed May 31, 2026